6.44

8.97% 0.53

Shattuck Labs Inc (STTK)

Overview News Price History Option Chain Financials Discussions Forecast

Shattuck Labs Inc stock is traded at $6.44, with a volume of 12.48M. It is up +8.97% in the last 24 hours and up +5.40% over the past month. Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Previous Close:

$5.91

Open:

$5.87

24h Volume:

12.48M

Relative Volume:

14.02

Market Cap:

$615.07M

Revenue:

$1,000.00K

Net Income/Loss:

$-48.81M

P/E Ratio:

-8.3236

EPS:

-0.7737

Net Cash Flow:

$-39.95M

1W Performance:

+30.10%

1M Performance:

+5.40%

6M Performance:

+92.24%

1Y Performance:

+544.00%

1-Day Range:

$5.75

$6.465

1-Week Range:

$5.00

$6.475

52-Week Range:

$0.712

$8.33

Shattuck Labs Inc Stock (STTK) Company Profile

Name

Shattuck Labs Inc

Sector

Healthcare (1096)

Industry

Biotechnology (615)

Phone

512-900-4690

Address

500 W. 5TH STREET, AUSTIN

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

STTK's Discussions on Twitter

Compare STTK vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STTK Shattuck Labs Inc	6.44	615.07M	1,000.00K	-48.81M	-39.95M	-0.7737
VRTX Vertex Pharmaceuticals Inc	491.34	124.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	632.90	66.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	887.18	55.17B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.37	38.90B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	182.08	38.71B	742.00K	-1.37B	-1.07B	-7.0731

Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	Cantor Fitzgerald	Overweight
Mar-06-26	Resumed	Needham	Buy
Jan-28-26	Initiated	Piper Sandler	Overweight
Dec-01-25	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-08-25	Initiated	Wedbush	Outperform
Mar-17-25	Initiated	Leerink Partners	Outperform
Oct-02-24	Downgrade	Citigroup	Buy → Neutral
Oct-02-24	Downgrade	Needham	Buy → Hold
Oct-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Aug-31-22	Initiated	BTIG Research	Buy
Jun-01-22	Initiated	Citigroup	Buy
May-02-22	Initiated	H.C. Wainwright	Buy
Apr-14-21	Initiated	Berenberg	Buy
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Citigroup	Buy
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Needham	Buy

View All

Shattuck Labs Inc Stock (STTK) Latest News

Jun 26, 2026

Price to sales forward of Shattuck Labs, Inc. – NASDAQ:STTK - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Shattuck Labs, Inc. – NASDAQ:STTK - TradingView

Jun 26, 2026